Patients with Adrenal Insufficiency may have higher Risk of Severe COVID-19

Written By :  Jacinthlyn Sylvia
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-10-23 05:45 GMT   |   Update On 2023-10-23 05:37 GMT

Patients with adrenal insufficiency (AI) face a significantly increased risk of severe outcomes from COVID-19, according to a recent Swedish national register-based cohort study. While they have a similar risk of contracting the virus as the general population, the study published in Journal of Internal Medicine revealed more than twofold increased risk of severe infection and a fatal outcome...

Login or Register to read the full article

Patients with adrenal insufficiency (AI) face a significantly increased risk of severe outcomes from COVID-19, according to a recent Swedish national register-based cohort study. While they have a similar risk of contracting the virus as the general population, the study published in Journal of Internal Medicine revealed more than twofold increased risk of severe infection and a fatal outcome for AI patients.

The study, conducted from January 2020 to February 2021, compared 5,430 patients with AI to a control group of 54,300 individuals from the general population, matching them by age and sex at a ratio of 10:1. The findings are eye-opening and could have substantial implications for the management and prioritization of healthcare for this group of patients.

The key results of the study were:

AI patients and the control group had similar rates of COVID-19 infection, indicating that AI itself does not increase the likelihood of contracting the virus.

However, when it came to severe outcomes, the disparities became stark. AI patients faced a substantially increased risk of hospitalization (2.1% vs. 0.8%), intensive care admission (0.3% vs. 0.1%), and death (0.8% vs. 0.2%) due to COVID-19 compared to the control group.

After adjusting for socioeconomic factors and comorbidities, the study reported increased hazard ratios (HR) for AI patients for hospitalization (1.96), intensive care admission (2.76), and death (2.29). These elevated risks highlight the vulnerability of AI patients to severe COVID-19 outcomes.

The findings underscore the importance of prioritizing AI patients for vaccination, antiviral therapy, and other appropriate treatments to reduce the risk of hospitalization and death due to COVID-19. While they are not more likely to contract the virus, AI patients are at a distinct disadvantage when it comes to the potential consequences of a COVID-19 infection.

Reference:

Bergthorsdottir, R., Esposito, D., Olsson, D. S., Ragnarsson, O., Dahlqvist, P., Bensing, S., Nåtman, J., Johannsson, G., & Nyberg, F. (2023). Increased risk of hospitalization, intensive care and death due to COVID‐19 in patients with adrenal insufficiency: A Swedish nationwide study. In Journal of Internal Medicine. Wiley. https://doi.org/10.1111/joim.13731

Tags:    
Article Source : Journal of Internal Medicine

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News